Is There a Role for FAPI PET in Urological Cancers?

IF 4.1 3区医学 Q1 GENETICS & HEREDITY

Molecular Diagnosis & Therapy Pub Date : 2024-08-24 DOI:10.1007/s40291-024-00735-9

Naima Ortolan, Luca Urso, Ilaria Zamberlan, Luca Filippi, Nicolò Maria Buffi, Corrado Cittanti, Licia Uccelli, Mirco Bartolomei, Laura Evangelista

{"title":"Is There a Role for FAPI PET in Urological Cancers?","authors":"Naima Ortolan, Luca Urso, Ilaria Zamberlan, Luca Filippi, Nicolò Maria Buffi, Corrado Cittanti, Licia Uccelli, Mirco Bartolomei, Laura Evangelista","doi":"10.1007/s40291-024-00735-9","DOIUrl":null,"url":null,"abstract":"<p><p>This work aims to investigate the utility of positron emission tomography/computed tomography (PET/CT) with fibroblast activation protein inhibitors (FAPI) in urological neoplasms, including prostate cancer, urothelial carcinoma, and renal cell carcinoma. Although the available data are very preliminary, FAPI PET showed potential for detecting primary prostate cancer with low prostate-specific membrane antigen expression, while prostate-specific membrane antigen PET/CT outperformed FAPI PET/CT in detecting biochemical recurrence. In urothelial carcinoma, FAPI PET/CT demonstrated increased detection rates compared with deoxy-2-[18F]fluoro-D-glucose PET/CT, in particular in small lymph node metastases, whose identification is still an unmet clinical need. Limited data are available for renal cell carcinoma. In conclusion, FAPI PET emerges as a promising imaging modality for urological neoplasms, in particular bladder cancer. Further research is warranted to establish its role in guiding therapeutic decisions and as a potential novel theranostic agent.</p>","PeriodicalId":49797,"journal":{"name":"Molecular Diagnosis & Therapy","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Diagnosis & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40291-024-00735-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

This work aims to investigate the utility of positron emission tomography/computed tomography (PET/CT) with fibroblast activation protein inhibitors (FAPI) in urological neoplasms, including prostate cancer, urothelial carcinoma, and renal cell carcinoma. Although the available data are very preliminary, FAPI PET showed potential for detecting primary prostate cancer with low prostate-specific membrane antigen expression, while prostate-specific membrane antigen PET/CT outperformed FAPI PET/CT in detecting biochemical recurrence. In urothelial carcinoma, FAPI PET/CT demonstrated increased detection rates compared with deoxy-2-[18F]fluoro-D-glucose PET/CT, in particular in small lymph node metastases, whose identification is still an unmet clinical need. Limited data are available for renal cell carcinoma. In conclusion, FAPI PET emerges as a promising imaging modality for urological neoplasms, in particular bladder cancer. Further research is warranted to establish its role in guiding therapeutic decisions and as a potential novel theranostic agent.

Abstract Image

查看原文本刊更多论文

FAPI PET 在泌尿系统癌症中发挥作用吗？

这项研究旨在探讨纤维母细胞活化蛋白抑制剂（FAPI）正电子发射断层扫描/计算机断层扫描（PET/CT）在泌尿系统肿瘤（包括前列腺癌、尿路上皮癌和肾细胞癌）中的应用。尽管现有数据还很初步，但 FAPI PET 显示出检测前列腺特异性膜抗原低表达的原发性前列腺癌的潜力，而前列腺特异性膜抗原 PET/CT 在检测生化复发方面的表现优于 FAPI PET/CT。在尿路上皮癌中，与脱氧-2-[18F]氟-D-葡萄糖 PET/CT 相比，FAPI PET/CT 的检出率更高，尤其是在小淋巴结转移方面，而对小淋巴结转移的识别仍是一项尚未满足的临床需求。肾细胞癌方面的数据有限。总之，对于泌尿系统肿瘤，尤其是膀胱癌，FAPI PET 是一种很有前景的成像模式。还需要进一步研究，以确定其在指导治疗决策中的作用，并将其作为一种潜在的新型治疗剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Diagnosis & Therapy 医学-药学

CiteScore

7.80

自引率

2.50%

发文量

审稿时长

>12 weeks

期刊介绍： Molecular Diagnosis & Therapy welcomes current opinion articles on emerging or contentious issues, comprehensive narrative reviews, systematic reviews (as outlined by the PRISMA statement), original research articles (including short communications) and letters to the editor. All manuscripts are subject to peer review by international experts.